Non-optimal methodology questions indirect treatment comparison of dupilumab vs. other biologics in severe asthma

We read with interest the article by Bateman E et al. [1] that attempted to evaluate the relative efficacies of dupilumab vs. benralizumab, mepolizumab, omalizumab, and reslizumab through an indirect treatment comparison (ITC). After careful review, we have concluded the methodology and results lack scientific robustness and credibility because individual trial and patient differences were not considered. Therefore, the conclusions drawn by the authors that “dupilumab was associated with statistically significantly lower annualized severe asthma exacerbation rates compared with benralizumab, mepolizumab, and reslizumab” and “statistically significantly greater improvement in lung function compared with benralizumab and reslizumab (at week 24) and omalizumab (at week 52)” are not credible.
Source: Respiratory Medicine - Category: Respiratory Medicine Authors: Tags: Correspondence Source Type: research